GAC - (FA) At a corporate presentation last spring it was stated that the BoM Clinical Stering Committee had decided to not do a FA at 125 MACE events as there had been another trial that was stopped at the halfway point that apparently did not give full enough information to their CSC to make the best learned decision at the time. In that particular situation that trial or some sort of retrial proved that it was a grave mistake and ended up costing that company(shareholders) a lot of time and money.

(SSRA) Don clearly stated at the Sept 2018 AGM that they decided not to do a SSRA as by the time the results would be available we would likely be done the BETonMACE trial. This clear communication seems to be missed by you. This change in path has saved the company a lot of money that would otherwise have created more dilution for all shareholders.

Every business has to make decisions on the fly depending on the circumstances and information they have to work with at that time. Seems to me that management is meeting its reporting requirements and opperating in an efficient manor, more or less. Neither of the above 2 events were material in nature and both were reported to anyone who paid attention. Both of these events were discussed on this board at the time it was presented.

tada